Sex, stroke, and atrial fibrillation

Archives of Neurology

Volumn 69, Issue 12, 2012, Pages 1641-1643

  Hart, Robert G ^a   Eikelboom, John W ^a   Pearce, Lesly A ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APIXABAN; DABIGATRAN; ESTROGEN; WARFARIN;

BLOOD CLOTTING; CEREBROVASCULAR ACCIDENT; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DRUG EFFICACY; HEART ATRIUM FIBRILLATION; HEMOSTASIS; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPHYLAXIS; RISK ASSESSMENT; SEX DIFFERENCE; SHORT SURVEY;

EID: 84871225804     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2012.2691     Document Type: Short Survey

References (26)

1. Halperin JL, Hart RG. Atrial fibrillation and stroke: new ideas, persisting dilemmas. Stroke. 1988;19(8):937-941.
2. Watson T, Shantsila E, Lip GYH. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. Lancet. 2009;373(9658):155-166.
3. Soderstrom N. Myocardial infarction and mural thrombosis in the atria of the heart. Acta Med Scand Suppl. 1948;217:51-52.
4. Goldman ME, Pearce LA, Hart RG, et al. Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation, I: reduced flow velocity in the left atrial appendage (the Stroke Prevention in Atrial Fibrillation [SPAF-III] Study). J Am Soc Echocardiogr. 1999;12(12):1080-1087.
5. Feinberg WM, Pearce LA, Hart RG, et al. Markers of thrombin and platelet activity in patients with atrial fibrillation: correlation with stroke among 1531 participants in the Stroke Prevention in Atrial Fibrillation III Study. Stroke. 1999;30(12):2547-2553.
6. Lip GYH, Lane D, Van Walraven C, Hart RG. Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation. Stroke. 2006;37(9):2294-2300. (Pubitemid 44337172)
7. Lip GYH, Patel JV, Hughes E, Hart RG. High-sensitivity C-reactive protein and soluble CD40 ligand as indices of inflammation and platelet activation in 880 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors, stroke risk stratification schema, and prognosis. Stroke. 2007;38(4):1229-1237. (Pubitemid 351664238)
8. Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology. 2007;69(6):546-554.
9. Boysen G, Nyboe J, Appleyard M, et al. Stroke incidence and risk factors for stroke in Copenhagen, Denmark. Stroke. 1988;19(11):1345-1353.
10. Stroke Prevention in Atrial Fibrillation Investigators. Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation: the Stroke Prevention in Atrial Fibrillation Study. J Stroke Cerebrovasc Dis. 1995;5(3):147-157. doi:http://dx.doi.org/10.1016/S1052-3057(10)80166-1.
11. Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW; the Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. Stroke. 1999;30(6):1223-1229. (Pubitemid 29259178)
12. Wang TJ, Massaro JM, Levy D, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA. 2003;290(8):1049-1056. (Pubitemid 37430445)
13. Fang MC, Singer DE, Chang Y, et al. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation. 2005;112(12):1687-1691. (Pubitemid 41368143)
14. Friberg J, Scharling H, Gadsbøll N, Truelsen T, Jensen GB; Copenhagen City Heart Study. Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women versus men (the Copenhagen City Heart Study). Am J Cardiol. 2004;94(7):889-894. (Pubitemid 39359174)
15. Coppens M, Eikelboom JW, Hart RG, et al. The CHA2DS2-VASC score identifies af patients with a CHADS2 score of 0 or 1 treated with antiplatelet therapy who are unlikely to benefit from oral anticoagulant therapy. J Am Coll Cardiol. 2012;59(13s1):E570-E570. doi:10.1016/S0735-1097(12)60571-3.
16. Friberg L, Benson L, Rosenqvist M, Lip GYH. Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study. BMJ. 2012;344:e3522. doi:10.1136/bmj.e3522.
17. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 2010;137(2):263-272.
18. Zabalgoitia M, Halperin JL, Pearce LA, Blackshear JL, Asinger RW, Hart RG; Stroke Prevention in Atrial Fibrillation III Investigators. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. J Am Coll Cardiol. 1998;31(7):1622-1626. (Pubitemid 28273307)
19. Asinger RW, Koehler J, Pearce LA, et al. Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation, II: dense spontaneous echocardiographic contrast (the Stroke Prevention in Atrial Fibrillation [SPAF-III] Study). J Am Soc Echocardiogr. 1999;12(12):1088-1096.
20. Avgil Tsadok M, Jackevicius CA, Rahme E, Humphries KH, Behlouli H, Pilote L. Sex differences in stroke risk among older patients with recently diagnosed atrial fibrillation. JAMA. 2012;307(18):1952-1958.
21. van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in non-valvular atrial fibrillation: an individual patient meta-analysis. JAMA. 2002;288(19):2441-2448. (Pubitemid 35340540)
22. Mant J, Hobbs FD, Fletcher K, et al; BAFTA investigators; Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007;370(9586):493-503. (Pubitemid 47212371)
23. Connolly SJ, Ezekowitz MD, Yusuf S, et al RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-1151.
24. Connolly SJ, Eikelboom J, Joyner C, et al AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806-817.
25. Granger CB, Alexander JH, McMurray JJ, et al ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992.
26. Churchill WS. Radio broadcast. October 1939.